Salvia BioElectronics Funding News- Dutch medtech Salvia BioElectronics Raises $60M Series B Funding

This therapy is a minimally invasive treatment for chronic migraine. The funding round was oversubscribed and led by Innovation Industries from Amsterdam. Other investors include Invest-NL, the EIC Fund, and previous supporters like Inkef, Panakès Partners, SHS Capital, Dolby Family Ventures, Brabant Development Agency (BOM), and Thuja Capital.

The new funds will help finish an important clinical study called RECLAIM, and support regulatory approvals and preparations for launching the therapy in the US, Europe, and Australia.

“With the support of this strong investor syndicate, we are empowered to bring MySalvia Therapy to patients in desperate need of new treatment options,” said Hubert Martens, founder and CEO of Salvia BioElectronics. “Chronic migraine is not ‘just a headache’. It is a debilitating neurological condition that forces people out of their social life, their work, and the life they want to live.”

Salvia BioElectronics, based in Eindhoven, is creating a small implant to help treat migraines. The device gently stimulates specific nerves to reduce how often and how bad migraine attacks are.

It uses two thin implants placed under the skin—one on the forehead and one on the back of the head. Patients can control it with a wearable device they use when needed.

Read Also -SCI Semiconductor Funding News- SCI Semiconductor Secures £2.5M Funding

This easy-to-use and less invasive treatment could help many people with chronic migraines who haven't found relief with usual medicines.

Migraine is one of the leading causes of disability worldwide, especially affecting young women. In Europe and the US, it costs about $110 billion every year because of missed work and healthcare expenses.

Many current treatments don’t provide long-lasting relief, and many patients stop using them within a year. Salvia aims to change this.

“Salvia BioElectronics is redefining the migraine therapy landscape with a bold, patient-centered approach that combines cutting-edge neuromodulation with an elegant, minimally invasive design,” said Caaj Greebe, Partner at Innovation Industries. “We are excited to partner with the Salvia team as they advance through their clinical development to deliver a meaningful new therapy.”

Salvia’s treatment has also gained support from regulators. MySalvia Therapy has received the FDA Breakthrough Device Designation, which helps speed up its approval in the United States.

The company is running the RECLAIM clinical trial in Europe and Australia and plans to start trials in the U.S. soon.

Neuromodulation, which uses electrical signals to treat pain and brain disorders, is becoming more popular. Migraines are a big area that still needs better treatments.

Salvia is part of a group of medtech companies developing new options beyond medicines, like devices for cluster headaches and nerve stimulation.

“We believe people with migraine deserve the opportunity to reclaim their lives,” Martens added. “With this funding, we are advancing toward regulatory approval and commercialization, with the ultimate goal of reaching millions of people affected by chronic migraine.”

About Salvia BioElectronics

Salvia BioElectronics is creating a new therapy to change how migraines are treated. The company was started in 2017 and is based in Eindhoven, The Netherlands. It is led by experienced experts in medical devices and nerve treatments. Salvia works in the US, Europe, and Australia and is testing its therapy with help from top investors. They are also looking into using their technology to treat cluster headaches.